The prize is awarded annually to researchers under the age of 45 who do translational research and who have demonstrated excellence in research early in their careers. Each recipient is awarded $12,000.
Pete Williams and his research team have focused on studying and understanding the changes in the eye that lead to glaucoma rather than managing the risk factors. Several studies on how nicotinamide (a variant of vitamin B) can slow down the degenerating processes and protect the optic nerve have led to the start of a larger clinical study in the spring of 2022.
– I am delighted to have been nominated and awarded this translational research award. It really demonstrates the importance of translational research – from bench to bedside – in developing new clinically applicable therapies for glaucoma.
Link to press release
Read more about Pete Williams' research